Wockhardt Ltd. Share Price

Wockhardt: Zaynich leads the next growth phase

Wockhardt Limited is pursuing a transition from a traditional pharmaceutical portfolio towards a research-led specialty pharma and biotechnology model. The long-term opportunity centres on novel antibiotic Zaynich, insulin and biosimilars, and a pipeline that includes GLP-1 molecules. Figures supplied for this draft: FY26 revenue approximately ₹3,373 crore; Q1 FY27 revenue ₹929 crore (+26% YoY); Q1 FY27 EBITDA approximately ₹188 crore; biotechnology revenue approximately ₹236 crore (+112% YoY); FY26 EBITDA approximately ₹630 crore and margin approximately 18.6%. These have not been independently verified here and must be reconciled with official filings before distribution. Analyst inputs: reference market price ₹2,084 (date not specified); stance: no recommendation; investment horizon: five years; position: no position, as declared by the analyst.

Wockhardt Pharma (WOCKPHARMA) has reported strong Q1 FY27

!WOCKPHARMA Wockhardt Pharma has reported results with a net profit of ₹107 crore, marking a sharp turnaround from losses last year. The company is focusing on biotech expansion, insulin launches, and has shareholder approval for a ₹3,000 crore capital raise. 📊 Wockhardt Pharma Latest News (September 2026) 🔑 Financial Highlights Revenue (Q1 FY27): ₹929 crore QoQ: Down 3.7% from ₹965 crore YoY: Up 25.9% from ₹738 crore Operating Profit: ₹192 crore YoY growth: 868% Net Profit (PAT): ₹107 crore YoY growth: 199% EBITDA Margin: Expanded to 20.2% EPS: ₹6.55 (vs. ₹10.23 in Mar 2026) 📈 Stock Market Performance NSE Price (22 Sept 2026): ₹2,212 BSE Price (22 Sept 2026): ₹2,217.60 1-Year Gain: +48% Promoter Holding: 49.1% Valuation: P/E ratio at 86.7, reflecting high investor expectations 🚀 Strategic Developments Capital Raise: Shareholder approval for up to ₹3,000 crore via QIP/public offerings. Biotech Focus: Expanding into insulin analogs and novel drugs. Pipeline: Targeting 50% of revenue from novel drugs within 5 years. Key Drug: Antibiotic Zaynich approved by CDSCO, with US launch expected by year-end. Peak Sales Target: $1.5 billion from Zaynich 📰 Industry Context Pharma Rally: Nifty Pharma index up 2% recently, with peers like Laurus Labs and Piramal Pharma also surging. Wockhardt Stock Movement: Up 75% in one month, hitting all-time highs on regulatory approvals. 📌 Key Takeaways for Investors Strong turnaround: From losses to consistent profitability. High growth potential: Driven by biotech and novel drug launches. Risks: Elevated valuation makes the stock sensitive to execution delays in insulin launches or margin pressures. Opportunity: Strategic capital raise and global expansion could fuel long-term growth.

PHARMA STOCKS RISE UP TO 6% AMID DEFENSIVE BUYING

Wockhardt Ltd - Weekly Top Gainer in Nifty 500

Wockhardt Ltd. has captured the market's full attention this week, comfortably leading the Nifty 500 index pack with an explosive weekly surge of 21.5%. While the broader benchmark bled over the past 5 trading sessions, this pharmaceutical player decoupled from the gloom to print a strong weekly high before concluding the Friday session with an LTP of ₹2,179.20. Wockhardt's massive rerating is fueled by an ongoing, high-stakes structural shift from a legacy generics business to an innovation-led biopharma powerhouse. The Zaynich Game-Changer: The absolute center of gravity for investor optimism is Zaynich, the company's novel, breakthrough antibiotic targeting multi-drug resistant superbugs. Having secured marketing authorization from the Indian drug regulator (DCGI) and massive regulatory nods like the US FDA, the drug is preparing for a multi-geography commercial launch. High-margin exclusivity on a critical global asset has investors pricing in a fundamentally altered revenue horizon.

Wockhardt - How far is too far from the average

Wockhardt Ltd – Bullish Breakout Setup Duscussion